The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT06058585
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,000 participants
- Registry
-
NCT06058585
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, India, New Zealand, Spain, Sri Lanka
- Registry status
- Recruiting
Technical summary
Registry record NCT06058585. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-04 (actual); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
- Acronym
- CAPTIVATE
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Finerenone
- Intervention (Drug)
- Placebo Finerenone
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo semaglutide
- Lead sponsor
- The George Institute
Record details
- Record id
cardio:ct-nct06058585- Content hash
f4d9afeedfce79e35b5044cc765c26c82950a1aa75a652d370074ed5310d629e